Novartis halts HCQ trial against Covid-19 amid shortage of participants
Team Udayavani, Jun 22, 2020, 11:18 AM IST
Swiss drugmaker Novartis has halted a clinical trial of hydroxychloroquine as a potential Covid-19 treatment due to “acute enrolment challenges” that made its completion infeasible
Novartis said, “The recruitment challenge facing our hydroxychloroquine trial has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable time frame to determine the efficacy of hydroxychloroquine in treating patients with Covid-19”
Novartis’ trial began in April and sought to test the drug in 440 hospitalized patients. It has taken decision to revoke emergency use authorization for hydroxychloroquine.
Novartis had donated up to 130 million doses of hydroxychloroquine, including millions in the United States.
Earlier, Several studies of the decades-old malaria drug including in Britain were recently halted after scientists concluded it was “useless” against Covid-19.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Low back pain, depression, headaches main causes of poor health: Study
Surgical options for Parkinson’s disease
Breast cancer to cause a million deaths a year by 2040: Lancet commission
Will to resist temptations, achieve goals more trustworthy than using apps, study finds
Govt directs e-commerce firms to remove drinks, beverages from ‘health drinks’ category
MUST WATCH
Latest Additions
Injuries don’t define you: Mohammed Shami shares rehab update
Shivakumar desperately wants to become CM, says K’taka BJP chief Vijayendra
Scribe throws lapel microphone towards Sharad Pawar in Baramati; cops give clean chit
India delivers first batch of BrahMos missiles to Philippines
Air India cancels Dubai flights due to operational disruptions